The Associated Press
June 7, 2010, 7:33AM ET
Abraxis' Abraxane meets cancer study goal
NEW YORK
Abraxis BioScience said its drug Abraxane met a key goal in improving the overall response rate in lung cancer patients.
The company said the drug, in combination with Taxol, improved the response rate by 31 percent when compared with patients only taking Taxol. The study involved 1,052 patients receiving initial treatment for lung cancer.
Abraxane is already approved as a breast cancer treatment.
Abraxis BioScience Inc., based in Los Angeles, announced the results Saturday and plans on presenting them Monday at the annual meeting of the American Society of Clinical Oncology in Chicago.
Most Popular Stories
- Three Types of People to Fire Immediately
- Lego Is for Girls
- Google's Spreading Tentacles of Influence
- Gatorade Goes Back to the Lab
- Impress Potential Investors in 12 Steps
- Three Types of People to Fire Immediately
- Which Is America's Best City?
- Lego Is for Girls
- Top B-School Stories of 2011
- Professional Women and a Secure Retirement
